BioCeuticals UltraBiotic 60 (60 capsules)

BioCeuticals UltraBiotic 60 (60 capsules) - supplement facts.JPG
BioCeuticals UltraBiotic 60 (60 capsules) - supplement facts.JPG

BioCeuticals UltraBiotic 60 (60 capsules)


UltraBiotic 60 is a combination of 10 probiotic strains providing patients with 60 billion CFU per capsule and may help maintain normal, healthy intestinal and urogenital flora.  

Provides the clinically trialled dose of LAB4 probiotics – Lactobacillus acidophilus (CUL 21 + CUL 60), Bifidobacterium bifidum (CUL 20) and B. animalis ssp. lactis (CUL 34) 

Dairy free and vegetarian friendly.

Add To Cart

LAB4 blend
IBS has been correlated with a lower amount of lactobacilli and bifidobacteria in the gut.[2] The altered composition and metabolic activity of the intestinal microbiota may be associated with activation of mucosal immunity and inflammation, suggesting a potential intervention strategy comprising both organisms.[3,4]

A significant improvement in the symptom severity score of IBS and in scores for quality of life, days with pain and satisfaction with bowel habit compared with the placebo group was observed over the 8-week intervention period using 25 billion CFU of LAB4.[3]

Use of lactobacillus probiotics to support urogenital health
Lactobacilli, the dominant microorganisms in the urinary tract, may decrease the proliferation and growth of uropathogens through competitive inhibition and the production of antimicrobial compounds.[5]

L. plantarum appears to possess properties to maintain urogenital health by adhering to the urogenital surface, reducing pH, inhibiting pathogenic microbial growth through hydrogen peroxide production.[6]

L. fermentum and L. rhamnosus have been clinically demonstrated to resist uropathogen colonisation and assist in the maintenance of healthy urogenital flora.[7]

Gastrointestinal function

One of the ways the normal colonic microflora, particularly lactobacilli and bifidobacteria, help support normal digestive function by contributing towards the host’s defence of the gastrointestinal tract by colonisation resistance and interactions with the immune system.[8]

L. acidophilus and L. casei are demonstrated to adhere to the intestinal mucosa and may block the adherence of enteropathogens.[9]

L. plantarum is most often associated with bacteriocin production,[9] which reduces the survival of competing pathogens.

  • If diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years, seek medical advice.
  • Not to be used in children under two years of age without medical advice.
  • Mild, temporary gastrointestinal disturbances, such as increased flatulence, may occur with amounts exceeding one billion live organisms. If this occurs reduce the dose, then gradually increase it over time.
  • It is recommended to take probiotics at least four hours away from antibiotics to limit a potential reduction in probiotic effectiveness.[10]

[1] Hill C, Guarner F, Reid G, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-514.
[2] Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 2012;7(4):e34938.
[3] Williams EA, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2008;29:97-103.
[4] Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 2014;20(27):8886-8897.
[5] Barrons R, Tassone, D. Use of lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 2008;30(3):453-468.
[6] Ro¨nnqvist D, Stro¨m H, Forsgren-Brusk U, et al. Selection and characterization of a Lactobacillus plantarum strain promising as a urogenital probiotic. Microbial Ecol Health Dis 2005;17:75-82.
[7] Reid G, Burton J, Devillard, E. The rationale for probiotics in female urogenital healthcare. MedGenMed 2004;6(1):49.
[8] Macfarlane GT, Cummings JH. Probiotics, infection and immunity. Curr Opin Infect Dis 2002;15:501-506.
[9] Fooks LJ, Gibson, GR. Probiotics as modulators of the gut flora. Br J Nutr 2002;88(Suppl 1):S39-49.
[10] Hawrelak JA. Probiotics. In: Pizzorno JE, Murray MT (Eds), Textbook of natural medicine, 3rd ed (pp.1195-1215). St Louis: Churchill Livingstone Elsevier, 2006.